Hartree Partners’s Celgene Corp CELG Stock Holding History

Hartree Partners’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,658	Closed	-$206K	–	31
2017 Q1	$206K	Buy	+1,658	New	+$198K	0.23%	29

Other funds holding CELG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hartree Partners's CELG Position: Q2 2017 in Review

Hartree Partners sold out of Celgene Corp (CELG) in Q2 2017, closing a stake of 1,658 shares — an estimated $206K sold.

Hartree Partners first reported a position in CELG in Q1 2017 and held it in 1 quarter. The position peaked at $206K in Q1 2017. 1,428 funds tracked by Wall St. Rank hold CELG as of Q2 2017.

Hartree Partners reported no remaining Celgene Corp position as of Q2 2017 after selling out during the quarter.
Hartree Partners sold 1,658 Celgene Corp shares in Q2 2017, an estimated $206K.
Hartree Partners first reported a position in Celgene Corp in Q1 2017 and held it in 1 quarter.
Hartree Partners's Celgene Corp position peaked at $206K in Q1 2017.
1,428 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2017.

Based on Hartree Partners's 13F filing for Q2 2017, filed 14 Aug 2017.